Taiyo commenced full-fledged CMO operations in 1998, securing contracts from major innovator pharmaceutical companies at a time when the outsourcing model was still relatively new to Japan's pharmaceutical industry.
Taiyo's CMO business utilizes the company's extensive technical capabilities in manufacturing a diverse range of generic drugs in its state-of-the-art manufacturing facilities. The CMO has built a strong reputation based on the company's passion and commitment to always achieving the highest possible quality of its manufactured products. At present, the CMO serves 56 major domestic and international innovators, with CMO contracts covering 215 product items. Including Taiyo's own original products, the company manufactures approximately 740 product items. The manufacturing technology needed to produce such a diverse range of products is unrivaled in Japan.
Taiyo's record of achievements in the CMO field
| Category | Number of CMO customers | Number of product items manufactured under contract |
|---|---|---|
 |
31 companies | 145 items |
 |
26 companies | 51 items |
 |
9 companies | 19 items |
| Total | 66 companies (some companies are counted in more than one category) |
215 items |
As of March 2008, the actual number of customers was 56 companies.
Types of products covered by Taiyo's CMO business
Formulations covered by Taiyo's CMO business
-
- Small-volume injectables
- Large-volume injectables (vials, bags)
- Lyophilized formulations
- Injectable powders
- Injectable emulsions
- Pre-filled syringe formulations (1 ml-100 ml syringes, glass syringes, plastic syringes)
-
- Granulized formulations (powders, granules, fine granules)
- Tablets for oral use (uncoated, film-coated, sugar-coated, orally disintegrating tablets, bi-layer tablets, tri-layer tablets)
- Ingestible tablets (troches)
- Capsules (hard capsules, liquid filling for hard capsules)
-
- Molded drugs for external applications (suppositories)
- Formulations for external applications (ointments, creams)
-
- Formulations for oral use and external applications (liquid formulations in stick-type dispensing packs, syrups, lotions)
- Ophthalmic solutions
-
- Solid formulations (uncoated tablets, coated tablets, granules, fine granules)
- Sterile formulations (liquid injectables, injectable powders, lyophilized formulations)
-
- Sterile formulations (liquid injectables, lyophilized injectables)
-
- A new type of outsourcing that provides a manufacturing environment and technology
Major customers
(Selected list of customers, listed in Japanese phonetic order)
| Asahi Kasei Pharma Corporation | Ajinomoto Co., Ltd. | Ajinomoto Medica Co., Ltd. |
| ASKA Pharmaceutical Co., Ltd. | Astellas Shizuoka Co., Ltd. | Asubio Pharma Co., Ltd. |
| Alfresa Pharma Corporation | Otsuka Pharmaceutical Co., Ltd. | Kyowa Hakko Kogyo Co., Ltd. |
| Kirin Brewery Co., ltd. | Sanofi-Aventis K.K. | Sunstar Inc. |
| Sanwa Kagaku Kenkyusho Co., Ltd. | Schering-Plough Animal Health K.K. | Shionogi & Co., Ltd. |
| Shiseido Co., Ltd. | ZERIA Pharmaceutical Co., Ltd. | Daiichi Sankyo healthcare Co., Ltd. |
| Taisho Pharmaceutical Co., Ltd. | Takeda Pharmaceutical Co., Ltd. | Mitsubishi Tanabe Pharma Corporation |
| Chugai Pharmaceutical Co., Ltd. | Tobishi Pharmaceutical Co., Ltd. | Toyama Chemical Co., Ltd. |
| Nissan Chemicals Co., Ltd. | Nipro Pharma Corporation | Bayer Ltd. |
| Hisamitsu Pharmaceutical Co., Ltd. | Pfizer Japan Inc. | Fuji Pharma Co., Ltd. |
| Hospira Japan Co., Ltd. | Hoya Corporation | Wyeth K.K. |
| Wakamoto Pharmaceutical Co., Ltd. | and others |
